Literature DB >> 19540125

Combined modality treatment of newly diagnosed glioblastoma multiforme in a regional neurosurgical centre.

Andrew J Gauden1, Andrew Hunn, Albert Erasmus, Pauline Waites, Arvind Dubey, Stanislaw J Gauden.   

Abstract

The "local experience" of the Stupp protocol was examined in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM) with particular emphasis given to the extent of surgical resection and its effect on survival. Thirty-one patients with newly diagnosed GBM who underwent combined modality treatment according to the Stupp protocol were assessed retrospectively. Variables assessed were the extent of surgery, size and site of the tumour, age and performance status. Primary end points were overall survival (OS) and progression-free survival (PFS). Median OS was 33 months for macroscopic tumour resection (9 patients; 29%), 15 months for debulking (15; 48%) and 9 months for biopsy (7; 22%). Macroscopic tumour resection resulted in significantly improved OS and PFS compared to the two less radical surgical options (p<0.001). Patients with GBM undergoing maximal resection of the tumour followed by adjuvant radiotherapy and chemotherapy have an improved survival compared to patients undergoing either subtotal resection or biopsy alone. This statistically significant survival benefit was achieved in a regional neurosurgical centre with minimal additional toxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19540125     DOI: 10.1016/j.jocn.2008.12.008

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  4 in total

1.  Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.

Authors:  Johanna Gerstein; Kea Franz; Joachim P Steinbach; Volkert Seifert; Claus Rödel; Christian Weiss
Journal:  Strahlenther Onkol       Date:  2011-10-28       Impact factor: 3.621

2.  Cathepsin L suppression increases the radiosensitivity of human glioma U251 cells via G2/M cell cycle arrest and DNA damage.

Authors:  Qing-qing Zhang; Wen-juan Wang; Jun Li; Neng Yang; Gang Chen; Zhong Wang; Zhong-qin Liang
Journal:  Acta Pharmacol Sin       Date:  2015-06-22       Impact factor: 6.150

3.  Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial" resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group.

Authors:  Michela Buglione; Paolo Borghetti; Sara Pedretti; Luca Triggiani; Marco Maria Fontanella; Giannantonio Spena; Salvatore Grisanti; Roberto Liserre; Luigi Pietro Poliani; Stefano Gipponi; Luigi Spiazzi; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2015-03-15       Impact factor: 3.469

4.  CRABP-II- and FABP5-independent responsiveness of human glioblastoma cells to all-trans retinoic acid.

Authors:  Shi-Lin Xia; Mo-Li Wu; Hong Li; Jia-Hui Wang; Nan-Nan Chen; Xiao-Yan Chen; Qing-You Kong; Zheng Sun; Jia Liu
Journal:  Oncotarget       Date:  2015-03-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.